Scilex Holding Company
As of Oct 22, 2026, Scilex Holding is in Stage 4, the downtrend phase, now in week 4 (since Sep 28, 2026). It closed at $2.47, 82.4% below its 52-week high and below its 200-day average, which is falling.
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is SCLX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SCLX among Drug Manufacturers - General20th of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
| …20 | SCLX | Stage 4 · wk 4 | 15 | −51.6% |
Scilex Holding: quick answers
What stage is Scilex Holding in?
As of Oct 22, 2026, Scilex Holding (SCLX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 28, 2026 and is in week 4. What the four stages mean
Is Scilex Holding in an uptrend?
No. Scilex Holding is in a Stage 4 downtrend. It trades 55.0% below its 200-day average, which is falling.
How far is Scilex Holding from its 52-week high?
Scilex Holding closed at $2.47 on Oct 22, 2026, 82.4% below its 52-week high of $14.02. Its 52-week low is $2.47.
How has Scilex Holding performed over the past year?
As of Oct 22, 2026, Scilex Holding is down 71.2% over the past year and down 69.7% so far in 2026.
Which sector and industry is Scilex Holding in?
Scilex Holding is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA; and Tulex Master, which develops, tests, and manufactures clinical supplies of SP-104. Scilex Holding Company is based in Palo Alto, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.